Pipeline

We are advancing therapeutic candidates for the treatment of chronic HBV in multiple clinical trials as well as research programs focused on the discovery of additional novel antiviral mechanisms for HBV and other viral diseases. More information about our clinical trials can be found at www.clinicaltrials.gov.

A pipeline strategy designed to free HBV patients from lifelong therapy and target other serious viral diseases

In our relentless pursuit to discover novel antivirals to treat serious viral diseases and to bring finite and curative treatments to HBV patients, our pipeline is focused on the following areas:

  • Potent, next generation core inhibitors designed to maximally block the formation of new cccDNA
  • Novel , bioavailable small molecule inhibitors of HBV and HDV viral entry that potently block infection of hepatocytes for both viruses
  • Novel, bioavailable, liver-focused small molecule agonists of the interferon pathway that are able to activate antiviral cellular responses as well as engage the innate and adaptive immune systems
  • Long-acting helicase inhibitor for recurring herpes simplex virus type 2 (HSV-2)
  • Pan-herpes polymerase inhibitor (NNPI) for transplant-associated infections

Potent next generation core inhibitors

We have two potent, next generation CI product candidates, ABI-H3733 (3733) and ABI-4334 (4334), both optimized for significantly increased potency against cccDNA formation and new virus production versus first-generation core inhibitors. A Phase 1 study of 3733 is ongoing and 4334, which has a potential best-in-class profile, is expected to initiate clinical studies in 2022.

Research programs advancing new small molecule compounds with novel targets and mechanisms

Our research team is focused on proprietary research that has the potential to accelerate progress toward HBV cures and to discover novel antivirals to treat other serious viral diseases. We are currently advancing an early-stage program evaluating a novel small molecule approach to inhibit viral entry for HBV and hepatitis delta virus (HDV), which is estimated to impact approximately 5 percent of those chronically infected with HBV – approximately 12 million people globally. We are also advancing our novel orally-bioavailable interferon-α receptor (IFNAR) agonist program that is designed to selectively activate the interferon-α pathway in the liver while reducing systemic exposure to improve tolerability. We have also recently announced our first research programs outside of HBV and HDV, a long-acting helicase inhibitor of HSV-2 for patients with recurrent genital herpes, and a pan-herpes NNPI for transplant-associated viral infections.

More information about our clinical trials can be found at www.clinicaltrials.gov.